Kisqali® (ribociclib) tablets for HR+/HER2- metastatic breast cancer

What Kisqali® Is and How It Works

Kisqali® is the brand name for ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used with endocrine therapy to treat hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) advanced or metastatic breast cancer. It is supplied as oral tablets and is taken once daily in repeating 28-day cycles. Many patients start at a total daily dose of 600 mg. Kisqali® helps slow tumor growth by blocking CDK4 and CDK6, which limits cancer cell division.

YouDrugstore is a licensed Canadian pharmacy based in Manitoba. Our pharmacists review prescriptions before we dispense. We offer brand and generic medicines at Canadian prices, and we also carry OTC health products. We serve US patients online with caring support and secure delivery. We work with vetted, licensed partner pharmacies internationally to supply authentic brands at affordable prices and a broad selection.

Dosage and Usage

Follow the treatment plan your oncology team prescribes. Label guidance includes these key points:

• Standard adult starting dose: 600 mg once daily (often written as 600mg), taken for 21 days on treatment followed by 7 days off, to complete a 28-day cycle.
• Administer with or without food at the same time each day.
• Swallow tablets whole. Do not crush, split, or chew.
• Use Kisqali® in combination with an aromatase inhibitor (such as letrozole or anastrozole) or with fulvestrant. Premenopausal patients typically also receive ovarian suppression (for example, with an LHRH agonist).
• Dose modifications: prescribers may reduce to 400 mg or 200 mg daily for side effects like neutropenia, liver enzyme elevation, or QT prolongation.
• Missed dose: if a dose is vomited or missed, do not take an extra dose that day. Take the next dose at the usual time.

Storage and travel:

• Store tablets at room temperature (15–30°C) in the original blister to protect from moisture.
• Keep out of reach of children and pets.
• When traveling, keep the blister packs in your carry-on. Bring enough for possible delays.
• Avoid heat, humidity, and direct sunlight.

Important interactions:

• Avoid strong CYP3A inhibitors (for example, ketoconazole, clarithromycin) and strong CYP3A inducers (for example, rifampin, carbamazepine, St. John’s wort). Your prescriber may adjust dosing if avoidance is not possible.
• Avoid grapefruit and grapefruit juice. Kisqali® and grapefruit juice can raise ribociclib levels and increase side effects.
• Review all medicines, supplements, and herbals with your care team to prevent interactions.

Benefits and Savings

Kisqali® combined with endocrine therapy has extended progression-free survival compared with endocrine therapy alone in multiple trials (MONALEESA program). Benefits include improved disease control, delay in chemotherapy need, and maintenance of daily function for many patients. Kisqali® offers oral dosing that fits home routines, with a 3-weeks-on/1-week-off schedule for most regimens.

Ordering from YouDrugstore can lower the monthly spend compared with typical US prices. Patients often save about 60–80% when comparing kisqali cost per month or kisqali price across borders. We provide clear billing in USD, helpful order updates, and discreet packaging.

Side Effects and Safety

All medicines can cause side effects. Oncology teams monitor blood counts, liver enzymes, and the heart rhythm (QT interval) during therapy.

• Common: neutropenia, leukopenia, infections, fatigue, nausea, vomiting, diarrhea, constipation, decreased appetite, headache, rash, cough, and hair thinning. Many patients search for kisqali hair loss; hair changes are usually mild and reversible.
• Serious: febrile neutropenia, severe infections, hepatotoxicity (elevated ALT/AST), QT prolongation and risk of arrhythmia, and interstitial lung disease/pneumonitis.
• Contact your clinic promptly for fever, chills, chest pain, shortness of breath, fainting, or yellowing of the skin or eyes.
• Monitoring: baseline and periodic ECGs and electrolytes for QT risk; complete blood counts; liver function tests.

Risk factors such as congenital long QT syndrome, electrolyte disturbances, or concurrent QT-prolonging medicines may increase the chance of arrhythmia. Prescribers consider these before starting therapy and may adjust the plan.

Onset Time

Laboratory changes, such as lower neutrophil counts, often appear in the first cycle. Symptom relief and radiographic responses may take several weeks. Many patients see the first assessment after 8–12 weeks, and clinicians adjust therapy based on response and tolerance over time.

Compare With Alternatives

Other CDK4/6 inhibitors include palbociclib and abemaciclib. All three are combined with endocrine therapy for HR+/HER2- advanced breast cancer.

Palbociclib (Ibrance) has a similar 21-days-on/7-days-off schedule. Neutropenia is common, like with ribociclib. QT prolongation risk is not a key issue for palbociclib.

Abemaciclib (Verzenio) is taken continuously, usually twice daily. Diarrhea is more frequent and often earlier, while neutropenia tends to be less severe than with ribociclib or palbociclib.

Choice depends on medical history, side-effect profiles, dosing preferences, drug interactions, and prior therapies. Your oncology team weighs these factors when selecting a regimen.

Combination Therapy

Kisqali® is used with an aromatase inhibitor (letrozole, anastrozole) as initial endocrine-based therapy, or with fulvestrant after progression on prior endocrine therapy. Premenopausal patients usually receive ovarian suppression with an LHRH agonist. Bone-modifying agents, such as bisphosphonates or denosumab, may be added for patients with bone metastases to reduce skeletal complications. Continue background endocrine therapy as directed while taking Kisqali®.

Patient Suitability and Cost-Saving Tips

Candidates generally include adults with HR+/HER2- advanced or metastatic breast cancer who can receive endocrine therapy. Caution applies in patients with significant cardiac history, electrolyte abnormalities, or baseline QT prolongation. Review medicines that affect CYP3A or the QT interval. Avoid Kisqali® during pregnancy and breastfeeding.

To manage costs, consider multi-month supply options when appropriate, as they can lower the per-month spend. We also offer gentle reorder reminders so you stay on track with therapy. For current deals and bulk offers, see our kisqali coupon.

For broader oncology education, explore Cancer resources on our site. Our articles on managing treatment effects can also help, such as Common Darzalex Side Effects And Tips To Manage Them and Understanding Calquence Medication For Cancer Treatment.

Authoritative Sources

Review trusted references for full details and prescribing guidance:

• Novartis Kisqali manufacturer page
• Health Canada Drug Product Database: ribociclib
• FDA Prescribing Information for Kisqali

You can order Kisqali® from YouDrugstore with a valid prescription. Our customer-service chat is available during posted office hours, and pharmacists can address medication questions. We provide prompt, express, cold-chain shipping where needed, with discreet packaging to the US.

This information is not a substitute for medical advice. Always discuss diagnosis, risks, and treatment decisions with your oncology team. Product availability, pack sizes, and pricing can change. We require a prescription to dispense.